Lastacaft — Medica

Preferred products

• generic azelastine hydrochloride 0.05% ophthalmic solution
• generic epinastine hydrochloride 0.05% ophthalmic solution
• prescription generic olopatadine 0.1% ophthalmic solution
• prescription generic olopatadine 0.2% ophthalmic solution

Initial criteria

• Patient has tried one Step 1 Product (generic azelastine hydrochloride 0.05% ophthalmic solution, generic epinastine hydrochloride 0.05% ophthalmic solution, prescription generic olopatadine 0.1% ophthalmic solution, or prescription generic olopatadine 0.2% ophthalmic solution).
• OR Patient requires the concurrent use of Alrex or generic loteprednol etabonate 0.2% ophthalmic suspension and an H1 antagonist or an H1 antagonist/mast cell stabilizer.
• OR Patient has tried a different ophthalmic steroid for the current condition.

Reauthorization criteria

• Same criteria as initial approval.

Approval duration

1 year